Abs#595 #ACR23 @RheumNow R Furie on 4 yr TULIP-LTE pts with b/l renal involvement 33% on anifrolumab continued to wk 208 vs PBO 6% Renal improvement at w208 in 9/10 pts, vs no avail PBO data Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement